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Renal replacement therapy in children and
adolescents
Leumann Ernst
Professor emeritus, University Children’s Hospital, Zurich, Switzerland
The authors of a study now published in Swiss Medical
Weekly [1] have made a large effort to combine data from
different sources over a long period in order to study:
1. The incidence of end stage renal disease (ESRD). Here
the upper age limit was 15.0 years to allow comparison
with the European Paediatric Registry (ESPN)
2. The primary diagnosis (until age 20 years), using con-
temporary diagnostic terms
3. The modalities of renal replacement therapy (RRT), in-
cluding data from adult registries and, if needed, from
individual and community registries
4. The long-term results of treatment, including beyond
the age of 20 years
Cui bono? It is legitimate to ask whether such a study mer-
its all this effort, as end-stage kidney disease in children
concerns only a small minority of all patients requiring
RRT. However, we have to look back to 1970, when the
present study [1] began: at that time, RRT was considered
to be a reasonable treatment modality for only a small mi-
nority of all patients, in fact only for those older than 15
and younger than 50 years [2]. Today, half of all dialy-
sis patients in Switzerland are older than 70 years [3]. In
1970, we had no clear idea how many paediatric patients
and with which diseases we would expect to see. Due to
the relatively small population of Switzerland, it was es-
sential to obtain data from the whole country, which has
not been easy, but is one of the strengths of this study. The
incidence calculated was 5.4 per million children per year;
the increase observed over the years is due to the fact that
during the first decade, children <5 years of age with ES-
RD were not always registered if they had no RRT.
Initially, no data were available about the spectrum of ES-
RD in children, although it was already evident that the
aetiology was very different from that in adults. It is a
strength of this study that diagnoses of ESRD were adapt-
ed to the present-day definitions, which are based on our
much better understanding of the mechanisms leading to
renal failure, thanks particularly to enormous progress in
genetics and insights into the pathophysiology of renal fail-
ure. The present study on patients up to the age of 20
years shows that about one third of ESRD cases are due to
each of monogenetic hereditary disease, CAKUT – a term
coined in 1999 by the group of Ichikawa [4] for congenital
anomalies of the kidney and urinary tract – and acquired
disease. The situation is thus very different from the one
in adult patients, where diabetic nephropathy, hypertensive
nephropathy and polycystic kidney disease are now among
the leading causes. An advantage is that in almost every
paediatric renal patient, a firm diagnosis can be made – this
is also in contrast to the situation in adult patients with re-
nal failure.
Paediatric and adult nephrology can both learn a lot from
each other. In particular, the spectrum of mono-genetic dis-
eases, mainly a paediatric domain, has expanded tremen-
dously. A prominent example is medullary cystic disease /
nephronophthisis, which affected 11.2% of all patients up
to the age of 20 years. The steroid-resistant nephrotic syn-
drome, which was due to monogenetic disorders in 7.1%
(and to acquired disease in 9%), is also important. How-
ever, there is a large heterogeneity both in the phenotype
(even within families) and in the genotype of many dis-
eases. Currently, more than twenty and thirty genes re-
spectively have been found for nephronophthisis and for
the steroid-resistant nephrotic syndrome [5, 6]. Such diag-
noses are now also increasingly observed in adult patients,
either in ESRD occurring at adult age or in former paedi-
atric patients who have reached adulthood.
Unlike the situation in adults, renal transplantation in pae-
diatric patients is always the ultimate goal, as dialysis is
considered a temporary measure. However, there is a se-
rious lack of kidneys from deceased donors. Fortunately,
since 2007 Swiss law has given some priority to children
and adolescents waiting for a graft from a deceased donor.
Still, inserting a graft from a living, related donor – in the
majority of cases from one of the parents – is a valuable
alternative. However, this is not possible in all cases. Live
donor transplantation was introduced in Zurich only in
1986, by which time rejection could be better controlled,
particularly by the introduction of ciclosporin. The optimal
solution, although often not possible, is to start RRT direct-
ly with renal transplantation, thus circumventing dialysis
(so called pre-emptive transplantation). This was achieved
in 29% of all paediatric and adolescent patients during the
years 2001–2015.
RRT in children is very demanding, not only regarding the
somatic aspects, including nutrition and growth, but also
the psychosocial side. Much can be achieved with school-
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ing and dialysis camps (which have been carried out yearly
since 1981) and other social activities. The five-year sur-
vival rates have steadily increased, to 94% for patients and
to 89% for grafts, in the fourth decade of the present study.
One as yet unsolved problem is recurrence of the primary
disease in the transplanted kidney, particularly in nephrotic
syndrome with focal segmental sclerosis without a genetic
cause [7], in C3 glomerulopathy [8] and in atypical
haemolytic uremic syndrome [9]. However, considerable
progress in understanding the mechanisms behind and in
the prevention of recurrent disease has been made recently
[7, 9].
A serious problem (not dealt with in the paper) was poor
growth, mainly due to the administration of high doses of
prednisone to treat and prevent rejection. This was a ma-
jor issue before the cyclosporine era. By preventing renal
osteodystrophy, improving nutrition, use of human growth
hormone and minimising steroid dosage, steady progress
can be achieved, the goal being nearly normal growth. We
are optimistic that progress will continue. Still, many of us
were overly optimistic, expecting that immunosuppression
could be replaced by lifelong tolerance by the year 2000.
Indeed, a Swiss pilot study (interventional clinical trial) to
induce immunological tolerance after renal transplantation
in adults is ongoing (www.swisstolerance.ch). Therefore,
20 years later, we are one step closer to that dream.
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